No. 019 · GH & Growth · Muscle Growth
ACE-031
Also known as: RamaterceptActRIIB-Fc
- Not FDA approved
- WADA ✗ S4
No sequence on file. We only draw fingerprints from published sequences — this ring motif is a placeholder, never a guessed sequence.
Evidence
- D In vitro
- C Animal
- B Human pilot
- A RCT
- S Approved
TIER A — At least one published randomized controlled trial in humans.
Randomized, placebo-controlled trials were run in healthy volunteers and boys with Duchenne muscular dystrophy; the DMD study was halted over safety signals.
Tiers rate the strength of published evidence — not effectiveness, safety, or a recommendation.
At a glance
- Routes studied
- Subcutaneous, Intravenous Routes used in published research
- FDA
- Not approved
- WADA
- Prohibited · S4 Hormone and metabolic modulators
Overview
A soluble activin receptor type IIB-Fc fusion protein that traps myostatin and related ligands. It was developed for muscle wasting but clinical trials were halted due to off-target effects.
Research status Phase II trials for Duchenne muscular dystrophy (halted due to epistaxis/telangiectasias); proof-of-concept demonstrated
Mechanism
ACE-031 is a soluble ActRIIB-Fc fusion protein that acts as a ligand trap, binding and neutralizing myostatin, activin A, GDF-11, and other TGF-beta superfamily members before they can signal through cell-surface receptors. This broad ligand sequestration promotes robust muscle hypertrophy and reduces fat mass but also explains the off-target vascular effects.
Effects reported in research
Reported outcomes, not promises. Some come from controlled human trials; others may be from smaller or preclinical studies — check the studies below.
- Robust myostatin pathway inhibition
- Significant lean mass gains in trials
- Reduced fat mass
- Potential bone mineral density improvement
Safety & unknowns
Phase II trials in Duchenne muscular dystrophy were halted due to epistaxis and telangiectasias (likely from BMP9/10 trapping affecting vascular biology). Lean mass gains were confirmed in humans. Demonstrates the risk of broad ligand-trap approaches. Not FDA-approved; development discontinued.
Unknowns. Trial safety data apply to the populations, formulations and conditions studied.
Informational only — not medical advice. peptidemeta publishes no dosing, protocols, or sourcing. Talk to a qualified clinician about any treatment decision.
Studies [0]
No studies cited for this entry yet.
Status sources
Sources behind the tier, regulatory status, sequence and dates on this page.
- Attie et al. 2013, Muscle Nerve (phase 1 RCT) pubmed.ncbi.nlm.nih.gov
- Campbell et al. 2017, Muscle Nerve (DMD trial) pubmed.ncbi.nlm.nih.gov
- WADA 2026 Prohibited List wada-ama.org
Cite this entry
peptidemeta. (2026). ACE-031. In peptidemeta: The peptide library, ranked by evidence. Retrieved November 8, 2026, from https://peptidemeta.com/p/ace-031/
@misc{peptidemeta-ace-031,
title = {ACE-031},
author = {{peptidemeta}},
year = {2026},
howpublished = {\url{https://peptidemeta.com/p/ace-031/}},
note = {Accessed 2026-11-08}
} Accessed date reflects when you opened this page. Cite primary studies for scientific claims.